Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

3319 - 89Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation in a dose-dependent manner and role of IL-2 receptor-binding


08 Oct 2016


Developmental therapeutics


Catharina Menke-van der Houven van Oordt


Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368


C.W. Menke-van der Houven van Oordt1, E. van Brummelen2, T. Nayak3, M. Huisman4, L. de Wit- van der Veen5, E. Mulder4, O. Hoekstra4, M. Stokkel5, G.A. van Dongen4, H.M. Verheul1, M. Feilke6, C. Guizani3, E. Guarin3, S. Evers7, J. Saro7, J.H.M. Schellens2

Author affiliations

  • 1 Medical Oncology, Vrije University Medical Centre (VUMC), 1081HV - Amsterdam/NL
  • 2 Clinical Pharmacology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 3 Roche Pharma Research And Early Development, Roche Innovation Centre, Basel/CH
  • 4 Nuclear Medicine And Radiology, Vrije University Medical Centre (VUMC), Amsterdam/NL
  • 5 Nuclear Medicine, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 6 Roche Pharma Research And Early Development, Roche Innovation Centre, Prentsberg/DE
  • 7 Roche Pharma Research And Early Development, Roche Innovation Centre, Zürich/CH


Abstract 3319


CEA-IL2v (cergutuzumab amunaleukin, RG7813) is an engineered IL-2 variant (IL-2v) antibody directed against Carcinoembryonic Antigen (CEA) with abolished IL-2 receptor (IL-2R) α (CD25) binding. The molecule was designed to improve the pharmacological and safety profile of IL-2 and direct local accumulation in CEA-positive (CEA+) tumors. To demonstrate selective and specific tumor targeting, CEA-IL-2v was labeled with 89Zr. Biodistribution and tumor accumulation was assessed at varying doses in tumors with different CEA status.


Patients (pts) with advanced and/or metastatic solid CEA+ or CEA-negative (CEA-) tumors were eligible for this sub-study of a phase I trial. CEA-IL2v was administered intravenously q2W at total doses of 6 mg, 20 mg and 30 mg (incl 50 MBq/2mg 89Zr-CEA-IL2v). All pts underwent up to 3 89Zr-PET assessments during cycle 1. In the 20 mg cohort, pts with initial tumor uptake at cycle 1 underwent additional 89Zr-PET assessments in cycle 4.


Patients were treated with 6 mg (4 pts CEA + ; 3 pts CEA-), 20 mg (8 pts CEA+) or 30 mg CEA-IL2v (4 pts CEA + ; 4 pts CEA-). Accumulation of 89Zr-CEA-IL-2v (at day 5 post injection) was observed independent of CEA status in lymphoid tissues like spleen (SUVmean 10.0 ± 3.1) and non-pathological lymph nodes (SUVmean 2.0 ± 1.2) at all doses; this was considered IL-2 receptor-mediated uptake. Intratumoral accumulation of 89Zr-CEA-IL-2v in cycle 1 was observed in CEA+ patients: 1/4 pts at 6 mg (SUVpeak 5.4), 6/8 pts at 20 mg (SUVpeak 5.2 ± 2.7) and 4/4 pts at 30 mg (SUVpeak 5.8 ± 4.4). At cycle 4, 89Zr-CEA-IL-2v accumulation in tumor lesions (SUVpeak 4.0 ± 1.1) decreased, possibly due to anti-drug antibodies or expansion of IL-2R expressing T-cells. In tumors with high accumulation of 89Zr- CEA-IL-2v at cycle 1, there was a trend towards decreased metabolic activity at early FDG-PET evaluation.


At all doses, 89Zr- CEA-IL-2v accumulated in spleen and secondary lymphoid tissues, due to IL-2R mediated uptake. CEA-mediated tumor accumulation was observed in a dose-dependent manner with consistent targeting starting at 20 mg CEA-IL2v; a phase I study as monotherapy and with atezolizumab is ongoing.

Clinical trial identification

ClinicalTrials.gov Identifier:NCT02004106 EUDRACT NUMBER: 2013-003041-41

Legal entity responsible for the study

F. Hoffmann-La Roche Ltd.


F. Hoffmann-La Roche Ltd


T. Nayak: Employement and stock/ownership Hoffman LaRoche. H.M. Verheul: Honoraria and consulting/advisory role for Boehringer Ingelheim- recipient: Institution. Reserach Funding of AMGEN, VHS, ImmunonovoBV, Roche - recipient: Institution. M. Feilke: Consulting/advisory role for Roche Diagnostics GmbH Travel/ accomodation expenses received from Roche Diagnostics GmbH. C. Guizani: Employement of Hoffmann-LaRoche Stock/ownership Hoffmann-LaRoche. E. Guarin: Employment Hoffmann-LaRoche. S. Evers: Employment Roche Glycart Leadership Roche Glycart Stock/ownership F Hoffmann-LaRoche. J. Saro: Employment Roche Glycart Stock/ownership Roche and BMS. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings